These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 24221641)

  • 1. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
    Gold R; Comi G; Palace J; Siever A; Gottschalk R; Bijarnia M; von Rosenstiel P; Tomic D; Kappos L;
    J Neurol; 2014 Feb; 261(2):267-76. PubMed ID: 24221641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
    N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.
    Laroni A; Brogi D; Morra VB; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL;
    BMC Neurol; 2014 Apr; 14():65. PubMed ID: 24690227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vagomimetic effects of fingolimod: physiology and clinical implications.
    Vanoli E; Pentimalli F; Botto G
    CNS Neurosci Ther; 2014 Jun; 20(6):496-502. PubMed ID: 24836740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis.
    Saida T; Kikuchi S; Itoyama Y; Hao Q; Kurosawa T; Nagato K; Tang D; Zhang-Auberson L; Kira J
    Mult Scler; 2012 Sep; 18(9):1269-77. PubMed ID: 22354739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L;
    Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.
    Voon V; Saiva L; O'Kelly S; Keane D
    Eur J Clin Pharmacol; 2014 Mar; 70(3):373-5. PubMed ID: 24309839
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
    Széplaki G; Merkely B
    Ideggyogy Sz; 2012 Nov; 65(11-12):369-76. PubMed ID: 23289171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fingolimod in a patient with Wolff-Parkinson-White syndrome.
    Huys AC; Lalive PH; Sekoranja L
    Mult Scler; 2014 Apr; 20(5):636-7. PubMed ID: 23897641
    [No Abstract]   [Full Text] [Related]  

  • 12. First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
    Hughes B; Cascione M; Freedman MS; Agius M; Kantor D; Gudesblatt M; Goldstick LP; Agashivala N; Schofield L; McCague K; Hashmonay R; Barbato L;
    Mult Scler Relat Disord; 2014 Sep; 3(5):620-8. PubMed ID: 26265274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral fingolimod (FTY720) for relapsing multiple sclerosis.
    Kappos L; Antel J; Comi G; Montalban X; O'Connor P; Polman CH; Haas T; Korn AA; Karlsson G; Radue EW;
    N Engl J Med; 2006 Sep; 355(11):1124-40. PubMed ID: 16971719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait.
    Al-Hashel J; Ahmed SF; Behbehani R; Alroughani R
    CNS Drugs; 2014 Sep; 28(9):817-24. PubMed ID: 25011422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rebound of disease activity during pregnancy after withdrawal of fingolimod.
    Sempere AP; Berenguer-Ruiz L; Feliu-Rey E
    Eur J Neurol; 2013 Aug; 20(8):e109-10. PubMed ID: 23829238
    [No Abstract]   [Full Text] [Related]  

  • 17. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
    Scott LJ
    CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease.
    Thomas K; Schrötter H; Halank M; Ziemssen T
    BMC Neurol; 2014 Jun; 14():126. PubMed ID: 24906818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.
    Sanford M
    Drugs; 2014 Aug; 74(12):1411-33. PubMed ID: 25063048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.
    Limmroth V; Ziemssen T; Lang M; Richter S; Wagner B; Haas J; Schmidt S; Gerbershagen K; Lassek C; Klotz L; Hoffmann O; Albert C; Schuh K; Baier-Ebert M; Wendt G; Schieb H; Hoyer S; Dechend R; Haverkamp W
    BMC Neurol; 2017 Jan; 17(1):11. PubMed ID: 28100182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.